The Broad Institute

The Broad Institute
Name	The Broad Institute
Established	2004
Type	Biomedical and genomic research
Headquarters	Cambridge, Massachusetts
Key people	Todd Golub, Deborah Hung, Stuart Schreiber
Affiliations	Massachusetts Institute of Technology, Harvard University, Harvard Medical School
Website	https://www.broadinstitute.org

The Broad Institute is a biomedical and genomic research center located in Cambridge, Massachusetts. It was founded as a collaborative partnership between the Massachusetts Institute of Technology, Harvard University, and its affiliated hospitals. The institute is dedicated to accelerating the understanding and treatment of disease by empowering a community of researchers across traditional institutional boundaries. Its work spans foundational science, translational medicine, and data science, aiming to transform biology and medicine.

History and founding

The institute was formally launched in 2004 following a decade of pioneering collaboration in genomics between scientists at MIT and Harvard University. A foundational $100 million gift from philanthropists Eli and Edythe Broad established the center, with the explicit goal of creating a new, nimble model for collaborative biomedical science. This built upon the success of the earlier Whitehead Institute/MIT Center for Genome Research, which had played a central role in the international Human Genome Project. The founding director was Eric Lander, a key leader in the Human Genome Project and a professor at both MIT and Harvard Medical School. In its early years, the institute rapidly expanded its scientific scope and physical footprint, moving into its current flagship building at 415 Main Street in Cambridge, Massachusetts in 2006.

Research focus and programs

Research is organized into interdisciplinary scientific programs and platforms that tackle broad challenges. Core areas include the study of the genetic basis of human disease through initiatives like the Stanley Center for Psychiatric Research and the Cancer Program. The Klarman Cell Observatory and the Metabolism Program investigate fundamental biological mechanisms. A major focus is on developing and applying new technologies in areas like CRISPR genome editing, single-cell genomics, and proteomics. The institute also houses major data science and computational biology efforts, such as the Data Sciences Platform, which manages and analyzes large-scale biomedical datasets. These programs often work in concert, as seen in large-scale population genomics projects like the All of Us Research Program.

Organizational structure and leadership

The institute operates as a 501(c)(3) nonprofit organization and is governed by a board chaired by the president of Harvard University and the president of the Massachusetts Institute of Technology. Day-to-day scientific leadership is provided by a director and a team of institute scientists and core faculty members. Todd Golub serves as the director and is also a professor at Harvard Medical School and an investigator at the Howard Hughes Medical Institute. The faculty includes renowned researchers like Deborah Hung, co-director of the Infectious Disease and Microbiome Program, and Stuart Schreiber, a pioneer in chemical biology. The structure is designed to be non-departmental, encouraging collaboration across traditional academic silos among scientists from MIT, Harvard University, and the Harvard-affiliated hospitals.

Key scientific contributions

Scientists have made transformative contributions across biomedicine. They played a leading role in the international Human Genome Project and subsequent efforts like the ENCODE project and the 1000 Genomes Project, which mapped human genetic variation. The institute was central to the discovery and development of CRISPR-Cas9 as a tool for genome editing, through the work of Feng Zhang. It has launched large-scale efforts to understand the genetic roots of diseases, including schizophrenia, autism, type 2 diabetes, and coronary artery disease, through consortia like the Psychiatric Genomics Consortium. Other major advances include creating the Cancer Cell Line Encyclopedia, pioneering Connectivity Map in chemical biology, and contributing foundational research during the COVID-19 pandemic through viral sequencing and surveillance.

Facilities and collaborations

The primary research facilities are located in the Kendall Square neighborhood of Cambridge, Massachusetts, with additional laboratory space in nearby buildings. The institute operates state-of-the-art scientific platforms, including the Genomics Platform, one of the largest genome sequencing centers in the world, and the Proteomics Platform. It engages in an extensive network of global collaborations, working with hundreds of institutions worldwide. Key partners include the McGovern Institute for Brain Research at MIT, Dana–Farber Cancer Institute, Massachusetts General Hospital, and the Brigham and Women's Hospital. International partnerships span institutions like the University of Tokyo, Wellcome Sanger Institute, and the African Centre of Excellence for Genomics of Infectious Diseases.

Funding and governance

Operations are supported by a mixed funding model that includes major philanthropic gifts, competitive federal grants from agencies like the National Institutes of Health and the National Science Foundation, and partnerships with pharmaceutical and biotechnology companies. Founding and ongoing philanthropic support has come from the Broad Foundation, as well as other major donors like Ted Stanley and Karen and Gary Gladstone. The institute is overseen by a board that includes the presidents of MIT and Harvard University, representatives from the Broad Foundation, and other scientific and business leaders. This governance structure ensures alignment with its academic partners while maintaining the operational agility to pursue large-scale, high-risk biomedical research.

Category:Research institutes in Massachusetts Category:Genomics organizations Category:Harvard University Category:Massachusetts Institute of Technology